{
    "clinical_study": {
        "@rank": "132661", 
        "acronym": "SYNERGY", 
        "arm_group": {
            "arm_group_label": "Intergard Synergy Graft", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "Safety and performance of an anti-microbial vascular graft in the treatment of aneurysmal\n      and occlusive disease of the abdominal aorta."
        }, 
        "brief_title": "Performance and Safety of a Second Generation Antimicrobial Graft in Abdominal Position", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Abdominal Aorta Aneurysm", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Aortic Aneurysm", 
                "Aortic Aneurysm, Abdominal"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this multi center, single arm study is to demonstrate the safety and\n      performance of the Second Generation Anti-Microbial (InterGard Synergy) vascular graft in\n      the treatment of aneurismal and occlusive diseases of the abdominal aorta.\n\n      The primary endpoint is the assessment of primary and secondary graft patency. The secondary\n      endpoints were the assessment of adverse events and the assessment of triclosan and silver\n      contents in the serum over the time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient aged 18-85 years\n\n        Patient presenting with an aorto-iliac occlusion (obstruction of flow) or stenosis, or\n        aorto-iliac aneurysm and eligible for a revascularization with a bifurcated graft\n\n        Exclusion Criteria:\n\n        Patient treated as an emergency\n\n        Patient included in another investigation\n\n        Patient pregnant or lactating or woman of childbearing potential\n\n        Patient with a known allergy to the material device used (collagen, triclosan, silver)\n\n        Patient with previous aorto-iliac bypass or replacement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710878", 
            "org_study_id": "HR07-001"
        }, 
        "intervention": {
            "arm_group_label": "Intergard Synergy Graft", 
            "intervention_name": "Intergard Synergy Graft", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Anti-Infective Agents"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "CHRU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on", 
                        "country": "France"
                    }, 
                    "name": "CHU Jean Minjoz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France"
                    }, 
                    "name": "CHU Dupuytren"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Edouard Herriot"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital G. et R. Laennec"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Pompidou"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France"
                    }, 
                    "name": "CHU La Mil\u00e9trie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Krankenhaus Nordwest"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in Abdominal Position", 
        "other_outcome": {
            "description": "Serum levels prior to surgery, 1 day post-implant, discharge and 30 days", 
            "measure": "Secondary endpoint - levels of silver and triclosan", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days"
        }, 
        "overall_official": {
            "affiliation": "CHU La Mil\u00e9trie", 
            "last_name": "Jean-Baptiste Ricco, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Defined as uniterrupted flow with no interventions. Follow-up timeframes - 1, 6, 12, 24, and 36 months", 
            "measure": "Primary Graft Patency", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Follow-up timeframes - 1, 6, 12, 24, and 36 months", 
            "measure": "Secondary endpoint - assessment of AEs", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 36 months"
        }, 
        "source": "Maquet Cardiovascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maquet Cardiovascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}